retatrutide eli lilly press release 2024 2025 Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial Eli Lilly infiltrates anti-obesity market

Therefore, GLP-1 emerges as a therapeutic target for treating inflammatory diseases in the brain

If those first two sound familiar, it's because the current generation of weight loss medications already targets them

Akkermansia increases Multiple animal studies demonstrate that GLP-1 receptor agonists like semaglutide increase Akkermansia muciniphila populations in the gut

This evolving competition is expected to drive innovation in areas such as delivery devices, patient adherence tools, and real-world clinical data generation

It works primarily through AMPK activation and multiple metabolic pathways, not through direct GLP-1 receptor binding

Priority was given to publications from the past decade, including epidemiological studies, clinical trials and mechanistic research, with seminal older works cited where foundational